TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04463303

Intervention type: OTHER
Intervention: lung ultrasound
Description: patient with or without weaning induced pulmonary adema

Intervention type: OTHER
Intervention: lung ultrasound
Description: patient with or without weaning induced pulmonary adema
Study: NCT02399735

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low Dose NK cells ×4 times
Description: Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 5×10E9 NK cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Normal Dose NK cells ×4 times
Description: Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 1×10E10 NK cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Normal Dose NK cells ×8 times
Description: Received conventional treatment and NK cells once per two-week for the first four-month, at a dose of 1×10E10 NK cells.
Study: NCT00467636

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood glucose monitoring
Description: Regular pre and post meal blood glucose monitoring.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glulisine
Description: Sub cutaneous injection given twice daily for 3 days. Dosage titrated to body mass index and body weight (BMI \< 30 = 0.1 unit/kg. BMI \> 30 = 0.2 unit/kg)
Study: NCT00727727

Intervention type: DRUG
Intervention: Piribedil
Study: NCT03166683

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hemopatch
Description: Liver resection surgery with collagen and polyethylene glycol haemostatic/sealant patch placement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care include other sealant / hemostatic devices as patches or liquid/gels
Study: NCT01767961

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diagnostic imaging
Description: Undergo MBS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Correlative studies
Study: NCT04904172

Intervention type: DEVICE
Intervention: Masimo O3 Regional Oximetry
Description: wo electrodes will be attached to the forehead area and connected to the Near Infrared Spectroscopy device after the consent of the patients who apply to Ege University Hospital Emergency Service with acute ischemic stroke and who are planned to have intravenous thrombolytic and / or endovascular thrombectomy treatment or treatments, and / or their caregivers.
Study: NCT04681989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moving On After Breast Cancer
Description: After the MOVE-ABC interventional group participant completes their baseline assessment (T0) and been given the study survey by a research staff member she will receive the following:~1. Instructions on how to use the physical therapy-based education materials by a research staff member~2. a range of motion wand~3. a small ball~4. MOVE-ABC education booklet and video~The intervention group will complete 4 weekly follow-ups with a research staff member over the phone. The follow-ups will be completed in between the T0 (baseline) assessment, and the T1 (1 month after baseline) assessment.
Study: NCT01732991

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: prostatic photo-vaporization (PVP)
Description: Prostatic photo-vaporization using a lithium laser of 532nm wavelength (GREEN-LIGHT XPS™,American Medical Systems, Minnetonka, MN, USA) emitting by a fiber MoXy™ a maximum power of 180 W continuously. Using common practice and according to the CE labelling.
Study: NCT00835289

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids
Description: Omax3\[TM\] (Cenestra Health \[TM\]) is a 1 g softgel capsule containing 94.5% omega-3 fatty acids. Each serving size is a 1 gram capsule, which contains 690 mg of eicosapentanoic acid (EPA) and 182 mg of docosahexanoic acid (DHA). Inactive ingredients include: Vitamin E/Tocopherol 2294 ppm (in a carrier of partially hydrogenated vegetable oils including soybean oil), gelatin, glycerol, and purified water (components of the capsule shell). The study participants will be randomized to 3 softgel capsules a day for 6 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 capsules of matching corn oil placebo
Study: NCT01767961

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Correlative studies
Study: NCT02722213

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR).
Description: MBSR is a combination of mindfulness meditation, breathing practices, gentle yoga, and other relaxation techniques; it is taught in a manualized 8-week program, does not require special equipment, and can be practiced safely by people of all abilities
Study: NCT04460183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RESP301, a Nitric Oxide generating solution
Description: Product application requires inhalation using a standard handheld nebulizer.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants will receive institutional SOC for the treatment of COVID-19.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Participants will receive institutional SOC for the treatment of COVID-19.
Study: NCT00225914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: Paroxetine CR 12.5 mg/day; dosing may be adjusted up to 25 mg/day after two weeks, based on treatment response and tolerability

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects enter into a six-week, double blind phase, randomized in a 1:1 ratio to paroxetine CR 12.5 mg/day or matching placebo pill; dosing may be adjusted up to 25 mg/day after two weeks, based on treatment response and tolerability.
Study: NCT03372161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-102
Description: injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: injection
Study: NCT02941614

Intervention type: BEHAVIORAL
Intervention: Distress screening
Description: A brief depression and anxiety screening instrument, the Patient Health Questionnaire-9 (PHQ-9), will be administered to newly diagnosed breast cancer patients in the Distress Screening arm.
Study: NCT02012803

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: End to end suturation by Krackow locking loop surgical technique with 2-Fiber-Wire suture
Description: Operative treatment of achilles tendon rupture; End to end suturation by Krackow locking loop surgical technique with 2-Fiber-Wire suture and after operation identical protocol as conservative treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment of achilles tendon rupture
Description: Conservative treatment of achilles tendon rupture; 1 week equinus-cast without bearing, and then 6 week Vacoped orthosis with different equinus degrees and full weight bearing.
Study: NCT02227849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 analogue
Study: NCT01988506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin 2
Description: Induction period: repeated administration of low-dose IL-2 (1MUI/day, sc) during 5 consecutive days.Maintenance period: treatment with IL-2, 1MUI once every 15 days (except systemic lupus erythematosus's patients every 7 days) for 6 months
Study: NCT03533127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY01008
Description: LY01008+Carboplatin/Paclitaxel
Study: NCT02821325

Intervention type: OTHER
Intervention: MRI
Description: Patients undergoing a total knee arthroplasty, will undergo additional MRI's. One MRI pre-operatively.~2nd MRI post-operatively on day 1. 3rd MRI post-operatively on day 2.
Study: NCT03284060

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive remediation program
Description: Cognitive remediation program is a set of reeducation techniques and aims at restoring or compensating altered cognitive functions such as memory, attentional or executive functions, and social cognition. Therapists help individuals develop new information processing strategies designed to meet their needs and wishes. Specific therapeutic sessions are designed to generalize such strategies to everyday situations to reduce the impact of cognitive deficits on daily life. Thus, social cognitive training therapy helps the development of personal strategies specifically adapted to preserve skills and reduce the difficulties.~16 sessions (45 min) of cognitive remediation with the therapist are proposed, each session is composed of three parts:~1. pen and paper tasks focusing on specific emotion recognition component (20 min),~2. computerized tasks focusing on the same process (20 min),~3. a proposal of a home-based task (during 20 min).
Study: NCT00856323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: At qualifying exposure, participants will take 28 days' worth (at one pill per day) of 200 mg emtricitabine and 300 mg tenofovir DF (Truvada).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CM
Description: Participants will submit a urine sample every Monday, Wednesday, and Friday for 8 weeks (a total of 24 urine samples). Samples will be tested for methamphetamine metabolites.
Study: NCT02981056

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Johnson's Baby Top-To-Toe Wash
Description: During the study period, the different intervention products/regimens will be assigned to each group of subjects and replaced their daily wash and or body lotion products. Usage frequency: Ideally 7 times a week, at least 5 times a week, no more than once in the same day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Johnson's Baby Lotion
Description: During the study period, the different intervention products/regimens will be assigned to each group of subjects and replaced their daily wash and or body lotion products. Usage frequency: at least once a day, no more than twice in the same day.
Study: NCT03533127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab + Carboplatin/Paclitaxel
Study: NCT02981056

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Johnson's Baby Lotion
Description: During the study period, the different intervention products/regimens will be assigned to each group of subjects and replaced their daily wash and or body lotion products. Usage frequency: at least once a day, no more than twice in the same day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water (in lieu of bathing products)
Description: During the study period, the different intervention products/regimens will be assigned to each group of subjects and replaced their daily wash and or body lotion products. Usage frequency: Ideally 7 times a week, at least 5 times a week, no more than once in the same day.
Study: NCT02850497

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: optical coherence tomography at 6 months
Description: 6-month evaluation of malapposition and endothelization with the use of intracoronary optical coherence tomography

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: optical coherence tomography at 6 months
Description: 6-month evaluation of malapposition and endothelization with the use of intracoronary optical coherence tomography
Study: NCT02981056

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water (in lieu of bathing products)
Description: During the study period, the different intervention products/regimens will be assigned to each group of subjects and replaced their daily wash and or body lotion products. Usage frequency: Ideally 7 times a week, at least 5 times a week, no more than once in the same day.
Study: NCT04143230

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screening for PC by means of two different screening tools
Description: Screening of chronically ill patients admitted to an Internal Medicine Unit from the Emergency Department, for palliative care need, using of both the SIAARTI/NCCN screening tool (EST), and the Simplified Screening Tool (SST), derived from the first instrument.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening for PC by means of two different screening tools
Description: Screening of chronically ill patients admitted to an Internal Medicine Unit from the Emergency Department, for palliative care need, using of both the SIAARTI/NCCN screening tool (EST), and the Simplified Screening Tool (SST), derived from the first instrument.
Study: NCT02850497

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: optical coherence tomography at 6 months
Description: 6-month evaluation of malapposition and endothelization with the use of intracoronary optical coherence tomography
Study: NCT03982238

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Continuous subcutaneous insulin infusion therapy for 1 month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Continuous subcutaneous insulin infusion plus metformin (at least1000mg/day) for 1 month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Continuous subcutaneous insulin infusion plus metformin (10mg/day) for 1 month
Study: NCT01784588

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Solyx Single Incision Sling System
Description: Solyx Single Incision Sling System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Obtryx II Sling System
Description: Standard outside-in transobturator sling
Study: NCT01734707

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Allicor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic Allicor 150 mg tablet
Study: NCT03619993

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: On-body injector
Description: Medical device for subcutaneous injection of a supportive medicine (Pegfilgrastim) automatically after 27 hours after application of device.
Study: NCT00696579

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BCG
Description: 6 weekly instillations of Tice-strain BCG (Organon Teknika Corp.) as induction chemotherapy, with a dose of 5 x 108 CFU diluted in 50 mL of saline held in the bladder for 2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 14 days after II look-TURB the patients received 6 weekly instillations of Gemcitabine (Gemzar, Eli Lilly SpA), using a dose of 2000 mg diluted in 50 mL of saline held in the bladder for 2 hours
Study: NCT02264288

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3 x 10^6 cells
Description: 3 x 10\^6 cells administered on Study Days 1 and 8

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10 x 10^6 cells
Description: 10 x 10\^6 Human Placenta Derived cells (PDA-002) administered on Study Days 1 and 8
Study: NCT03619993

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: On-body injector
Description: Medical device for subcutaneous injection of a supportive medicine (Pegfilgrastim) automatically after 27 hours after application of device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre-filled syringe
Description: For subcutaneous injection of a supportive medicine (Pegfilgrastim).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre-filled syringe
Description: For subcutaneous injection of a supportive medicine (Pegfilgrastim).
Study: NCT01908140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium Bromide / Formoterol Fumarate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol / Fluticasone
Study: NCT03886441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone propionate
Description: Beclomethasone propionate inhaled twice daily during radiotherapy
Study: NCT01230320

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Denture fabrication technique
Description: Sequence of procedures involved with the fabrication of conventional complete dentures. Examples of common procedures are:~1. the reproduction of denture-bearing tissues by means of impression techniques and casts;~2. the registration of maxillo-mandibular relations;~3. try-in of artificial teeth and carved denture bases.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Denture fabrication technique
Description: Sequence of procedures involved with the fabrication of conventional complete dentures. Examples of common procedures are:~1. the reproduction of denture-bearing tissues by means of impression techniques and casts;~2. the registration of maxillo-mandibular relations;~3. try-in of artificial teeth and carved denture bases.
Study: NCT03417466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enlite 1 connected to iPro2 recorder
Description: Use Enlite Sensor over 144 hours (6 days) when inserted in the abdomen and used with the iPro2 in subjects age 14 - 75 years.
Study: NCT00959426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04620110
Description: Multiple oral doses of PF-04620110 will be given. The specific dose will depend on the cohort to which the subject is assigned Initial planned doses are 1, 3, 5, 10 and 20 mg but may be modified based on emerging PK and safety data.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be given placebo or PF-04620110. Anticipated total daily doses for Cohorts A, B, C, D, E, F and G are 1, 3, 5, 10 and 20 mg. In each Cohort 9 subjects will receive active treatment and 3 will receive placebo for 14 days. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses during the study based on ongoing safety, tolerability and PK results, but will not be projected to exceed established PK stopping criteria.
Study: NCT01809886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: 50 patients, aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with sugammadex 4 mg/kg when surgery is over, maintaining a profound block level until that point in time (no response to TOF and PTC\<2).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: 50 patients aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with neostigmine 0. 05 mg/kg and atropine 0.025 mg/kg (conventional reverser treatment) when surgery is over, maintaining a profound block level unit that point in time (no response to TOF and PTC\<2).
Study: NCT02945124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: K tape
Description: Applying K tape to children to the lower limb muscles during motor activities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: K tape
Description: Applying K tape to children to the lower limb muscles during motor activities.
Study: NCT02818140

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine TQL block
Description: Unilateral ultrasound-guided TQL block with 30 mL ropivacaine 0.75% 30 min prior to the surgical procedure

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Saline TQL block
Description: Unilateral ultrasound-guided TQL block with 30 mL of saline 0,9% 30 min prior to the surgical procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Study: NCT00005812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Study: NCT02084069

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Study: NCT00340834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25 mg
Description: Core: Patients self-administered fingolimod 1.25 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.~Extension: Patients self-administered fingolimod 1.25 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Description: Core: Patients self-administered fingolimod 0.5 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.~Extension: Patients self-administered fingolimod 0.5 mg capsules orally once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon β-1a 30 µg
Description: Core: Patients self-administered interferon β-1a 30 μg in an intramuscular (im) injection once weekly. In addition, they self-administered a fingolimod placebo capsule orally once daily.~Extension: Patients self-administered either fingolimod 1.25 mg or 0.5 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment.
Study: NCT04562545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Twin Block
Description: a modified twin block design including jack screws to facilitate incemental advancement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Twin Block Appliance set to maximum bite
Description: a traditional twin block set to maximum bite advancement at start of treatment
Study: NCT03024424

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early disclosure

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Late disclosure
Study: NCT02825147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Study: NCT03073408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Closed loop control for propofol administration guided by the BIS.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Manual control group: Propofol administration adjusted manually.
Study: NCT01815580

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atripla or Stribild
Description: Antiretroviral therapy
Study: NCT02329743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX-10045
Description: topical therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX-10045
Description: topical therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RX-10045
Description: topical therapy